4.59
-0.41(-8.20%)
Currency In USD
| Previous Close | 5 |
| Open | 5 |
| Day High | 5.01 |
| Day Low | 4.58 |
| 52-Week High | 13.53 |
| 52-Week Low | 4.36 |
| Volume | 92,176 |
| Average Volume | 191,371 |
| Market Cap | 249.73M |
| PE | -1.05 |
| EPS | -4.39 |
| Moving Average 50 Days | 6.2 |
| Moving Average 200 Days | 9.75 |
| Change | -0.41 |
If you invested $1000 in Alumis Inc. Common Stock (ALMS) since IPO date, it would be worth $345.11 as of March 14, 2025 at a share price of $4.59. Whereas If you bought $1000 worth of Alumis Inc. Common Stock (ALMS) shares 0 years ago, it would be worth $345.11 as of March 14, 2025 at a share price of $4.59.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alumis to Present at Leerink's 2025 Global Healthcare Conference
GlobeNewswire Inc.
Mar 10, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
GlobeNewswire Inc.
Mar 08, 2025 2:00 PM GMT
ESK-001 is a highly selective, next-generation oral tyrosine kinase 2 (TYK2) inhibitor currently under development in moderate-to-severe plaque psoriasis and systemic lupusPhase 2 OLE data of ESK-001 at 40 mg BID demonstrated sustained or increasing
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
GlobeNewswire Inc.
Mar 04, 2025 2:01 PM GMT
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheetSOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasd